Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
  • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/44—Antibodies bound to carriers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
  • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
  • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
  • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
  • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
  • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
  • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4

Definitions

• the present invention relates to a pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein.
• the invention relates to the area of medicine and can be used to inhibit the production or amplify the elimination of protein P24.
• P24 protein detected in the human body is known in the art (see Papadopulos- Eleopulos E, Turner VF, Papadimitriou JM. Is a positive western blot proof of HIV infection? Biotechnology (NY). 1993 Jun; 11 (6): 696-707).
• U.S. Patent No. 7,582,294 discloses a medicament for treating Benign Prostatic Hyperplasia or prostatitis by administration of a homeopathically activated form of antibodies to prostate specific antigen (PSA).
• PSA prostate specific antigen
• Ultra-low doses of antibodies to gamma interferon have been shown to be useful in the treatment and prophylaxis of treating diseases of viral etiology. See U.S. Patent No. 7,572,441 , which is incorporated herein by reference in its entirety.
• CD4 cluster of differentiation 4
• CD4 receptor of immune cells is a glycoprotein expressed on the surface of immune cells such as leucocytes, T helper cells, regulatory T cells, monocytes, macrophages, and dendrytic cells.
• CD4 is a member of the immunoglobulin superfamily.
• CD4 is a co-receptor that assists the T cell receptor (TCR) with an antigen-presenting cell.
• TCR T cell receptor
• CD4 amplifies the signal generated by the TCR by recruiting an enzyme, known as lymphocyte-specific protein tyrosine kinase, which is essential for activating many molecules involved in the signaling cascade of an activated T cell.
• CD4 also interacts directly with MHC class II molecules on the surface of the antigen-presenting cell using its extracellular domain.
• HIV-1 uses CD4 to gain entry into host T-cells and achieves this by binding of the viral envelope protein known as gp120 to CD4.
• the binding to CD4 creates a shift in the conformation of gp120 allowing HIV-1 to bind to a co-receptor expressed on the host cell.
• co-receptors are chemokine receptors CCR5 or CXCR4, which of these co-receptor is used during infection is dependent on whether the virus is infecting a macrophage or T-helper cell'.
• HIV inserts a fusion peptide into the host cell that allows the outer membrane of the virus to fuse with the cell membrane. See Miceli MC, Parnes JR (1993). "Role of CD4 and CD8 in T cell activation and differentiation”. Adv. Immunol. 53: 59-122.
• the present invention is directed to a pharmaceutical composition and method of inhibiting of production or amplifying of elimination of P24 protein.
• the solution to the existing problem is presented in form of a pharmaceutical composition for inhibiting of production or amplifying of elimination of P24 protein, which comprises activated-potentiated form of antibodies to CD4 receptor.
• the invention provides a pharmaceutical composition comprising an activated-potentiated form of an antibody to CD4 receptor.
• the pharmaceutical composition further comprises a solid carrier, wherein said activated- potentiated form of an antibody to CD4 receptor is impregnated onto said solid carrier.
• the pharmaceutical composition is in the form of a tablet.
• the pharmaceutical composition including said activated-potentiated form of an antibody to CD4 receptor is in the form of a mixture of C12, C30, and C200 homeopathic dilutions. It is specifically contemplated that said mixture of C12, C30, and C200 homeopathic dilutions is impregnated onto a solid carrier.
• the pharmaceutical composition including said activated-potentiated form of an antibody to CD4 receptor is in the form of a mixture of C12, C30, and C50 homeopathic dilutions. It is specifically contemplated that said mixture of C12, C30, and C50 homeopathic dilutions is impregnated onto a solid carrier.
• the activated -potentiated form of an antibody to CD4 receptor may be a monoclonal, polyclonal or natural antibody. It is specifically contemplated that the activated-potentiated form of an antibody to CD4 receptor is a polyclonal antibody.
• the invention provides activated-potentiated forms of antibodies to antigen(s) having sequences described in the specification and claimed in the appended claims.
• the pharmaceutical composition includes activated-potentiated form of an antibody to CD4 receptor prepared by successive centesimal dilutions coupled with shaking of every dilution. Vertical shaking is specifically contemplated.
• the invention provides a method of inhibiting of production or amplifying of elimination of P24 protein, said method comprising administering an activated -potentiated form of an antibody to CD4 receptor thereby inhibiting production or amplifying elimination of P24 protein.
• the activated-potentiated form of an antibody to CD4 receptor is administered in the form of pharmaceutical composition.
• the pharmaceutical composition is administered in the form of a solid oral dosage form which comprises a pharmaceutically acceptable carrier and said activated-potentiated form of an antibody to CD4 receptor impregnated onto said carrier.
• said solid oral dosage form is a tablet.
• the pharmaceutical composition may be administered in one to two unit dosage forms, each of the dosage form being administered from once daily to four times daily.
• the pharmaceutical composition is administered twice daily, each administration consisting of two oral dosage forms.
• the pharmaceutical composition is administered in one to two unit dosage forms, each of the dosage forms being administered twice daily. All variants and embodiments described with respect to the composition aspect of the invention may be used with the method aspect of the invention. DETAILED DESCRIPTION
• antibody as used herein shall mean an immunoglobulin that specifically binds to, and is thereby defined as complementary with, a particular spatial and polar organization of another molecule.
• Antibodies as recited in the claims may include a complete immunoglobulin or fragment thereof, may be natural, polyclonal or monoclonal, and may include various classes and isotypes, such as IgA, IgD, IgE, lgG1 , lgG2a, lgG2b and lgG3, IgM, etc. Fragments thereof may include Fab, Fv and F(ab')2, Fab', and the like.
• the singular "antibody” includes plural “antibodies.”
• activated-potentiated form or “potentiated form” respectively, with respect to antibodies recited herein is used to denote a product of homeopathic potentization of any initial solution of antibodies.
• Homeopathic potentization denotes the use of methods of homeopathy to impart homeopathic potency to an initial solution of relevant substance.
• 'homeopathic potentization may involve, for example, repeated consecutive dilutions combined with external treatment, particularly vertical (mechanical) shaking. In other words, an initial solution of antibody is subjected to consecutive repeated dilution and multiple vertical shaking of each obtained solution in accordance with homeopathic technology.
• the preferred concentration of the initial solution of antibody in the solvent ranges from about 0.5 to about 5.0 mg/ml.
• the preferred procedure for preparing each component, i.e. antibody solution is the use of the mixture of three aqueous or aqueous-alcohol dilutions of the primary matrix solution (mother tincture) of antibodies diluted 100 12 , 100 30 and 100 200 times, respectively, which is equivalent to centesimal homeopathic dilutions (C12, C30, and C200) or the use of the mixture of three aqueous or aqueous-alcohol dilutions of the primary matrix solution of antibodies diluted 100 12 , 100 30 and 100 50 times, respectively, which is equivalent to centesimal homeopathic dilutions (C12, C30 and C50).
• an antibody is in the "activated-potentiated” or “potentiated” form when three factors, are present.
• the "activated-potentiated” form of the antibody is a product of a preparation process well accepted in the homeopathic art.
• the "activated-potentiated” form of antibody must have biological activity determined by methods well accepted in modern pharmacology.
• the biological activity exhibited by the "activated potentiated” form of the antibody cannot be explained by the presence of the molecular form of the antibody in the final product of the homeopathic process.
• the activated potentiated form of antibodies may be prepared by subjecting an initial, isolated antibody in a molecular form to consecutive multiple dilutions coupled with an external impact, such as mechanical shaking.
• the external treatment in the course of concentration reduction may also be accomplished, for example, by exposure to ultrasonic, electromagnetic, or other physical factors.
• V. Schwabe "Homeopathic medicines", M., 1967, U.S. Patents Nos. 7,229,648 and 4,31 1 ,897 which are incorporated by reference in their entirety and for the purpose stated, describe such processes that are well-accepted methods of homeopathic potentiation in the homeopathic art. This procedure gives rise to a uniform decrease in molecular concentration of the initial molecular form of the antibody.
• the required homeopathic potency can be determined by subjecting the intermediate dilutions to biological testing in the desired pharmacological model.
• 'homeopathic potentiation may involve, for example, repeated consecutive dilutions combined with external treatment, particularly vertical (mechanical) shaking.
• an initial solution of antibody is subjected to consecutive repeated dilution and multiple vertical shaking of each obtained solution in accordance with homeopathic technology.
• the preferred concentration of the initial solution of antibody in the solvent preferably, water or a water-ethyl alcohol mixture, ranges from about 0.5 to about 5.0 mg/ml.
• the preferred procedure for preparing each component i.e.
• antibody solution is the use of the mixture of three aqueous or aqueous-alcohol dilutions of the primary matrix solution (mother tincture) of antibodies diluted 100 12 , 100 30 and 100 200 times, respectively, which is equivalent to centesimal homeopathic dilutions C12, C30 and C200 or the mixture of three aqueous or aqueous-alcohol dilutions of the primary matrix solution (mother tincture) of antibodies diluted 100 12 , 100 30 and 100 50 times, respectively, which is equivalent to centesimal homeopathic dilutions C12, C30 and C50.
• Examples of how to obtain the desired potency are also provided, for example, in U.S. Patent Nos. 7,229,648 and 4,31 1 ,897, which are incorporated by reference for the purpose stated.
• the procedure applicable to the "activated-potentiated" form of the antibodies described herein is described in more detail below.
• the claimed "activated-potentiated” form of antibody encompasses only solutions or solid preparations the biological activity of which cannot be explained by the presence of the molecular form of the antibody remaining from the initial, starting solution.
• the "activated-potentiated” form of the antibody may contain traces of the initial molecular form of the antibody, one skilled in the art could not attribute the observed biological activity in the accepted pharmacological models to the remaining molecular form of the antibody with any degree of plausibility due to the extremely low concentrations of the molecular form of the antibody remaining after the consecutive dilutions.
• the biological activity of the "activated-potentiated' form of the antibodies of the present invention is not attributable to the initial molecular is the "activated-potentiated” form of antibody in liquid or solid form in which the concentration of the molecular form of the antibody is below the Avogadro number.
• the "activated-potentiated" form of the antibodies contains molecular antibody, if any, at a concentration below the threshold dose for the molecular form of the antibody in the given biological model.
• the present invention provides a pharmaceutical composition that includes activated-potentiated form of antibodies to CD4 receptor, prepared according to the homeopathic technology of potentiation by repeated, consistent dilution and intermediate external action of shaking as described in more detail herein below.
• the pharmaceutical composition of the invention is particularly useful in inhibiting of production or amplifying of elimination of P24 protein.
• the pharmaceutical composition of the invention possesses unexpected therapeutic effect, which manifest itself in particular therapeutic effectiveness in treatment of diseases associated with increase in production of P24 protein.
• the pharmaceutical composition of the invention expands the arsenal of preparations available for inhibiting of production or amplifying of elimination of P24 protein.
• the pharmaceutical composition in accordance with this aspect of the invention may be in the liquid form or in solid form.
• Activated potentiated form of the antibodies included in the pharmaceutical composition is prepared from an initial molecular form of the antibody via a process accepted in homeopathic art.
• the starting antibodies may be monoclonal, or polyclonal antibodies prepared in accordance with known processes, for example, as described in Immunotechniques, G. Frimel, M., "Meditsyna", 1987, p. 9-33; "Hum. Antibodies. Monoclonal and recombinant antibodies, 30 years after" by Laffly E., Sodoyer R. - 2005 - Vol. 14. - N 1-2. P.33- 55, both incorporated herein by reference.
• Monoclonal antibodies may be obtained, e.g., by means of hybridoma technology.
• the initial stage of the process includes immunization based on the principles already developed in the course of polyclonal antisera preparation. Further antibodies, 30 years after" by Laffly E., Sodoyer R. - 2005 - Vol. 14. - N 1 -2. P.33- 55, both incorporated herein by reference.
• Monoclonal antibodies may be obtained, e.g., by means of hybridoma technology.
• the initial stage of the process includes immunization based on the principles already developed in the course of polyclonal antisera preparation. Further stages of work involve the production of hybrid cells generating clones of antibodies with identical specificity. Their separate isolation is performed using the same methods as in the case of polyclonal antisera preparation.
• Polyclonal antibodies may be obtained via active immunization of animals.
• suitable animals e.g. rabbits
• CD4 receptor the appropriate antigen
• the animals' immune system generates corresponding antibodies, which are collected from the animals in a known manner. This procedure enables preparation of a monospecific antibody-rich serum.
• the serum containing antibodies may be purified, for example by using affine chromatography, fractionation by salt precipitation, or ion-exchange chromatography.
• the resulting purified, antibody-enriched serum may be used as a starting material for the preparation of the activated-potentiated form of the antibodies.
• the preferred concentration of the resulting initial solution of antibody in the solvent preferably water or a water-ethyl alcohol mixture, ranges from about 0.5 to about 5.0 mg/ml.
• the preferred procedure for preparing each component of the combination drug according to the present invention is the use of the mixture of three aqueous-alcohol dilutions of the primary matrix solution of antibodies diluted 100 12 , 100 30 and 100 50 times, respectively, which is equivalent to centesimal homeopathic dilutions C12, C30, and C50 or diluted 100 12 , 100 30 and 100 200 times, respectively, which is equivalent to centesimal homeopathic dilutions C12, C30 and C200.
• a solid carrier is treated with the desired dilution obtained via the homeopathic process.
• the carrier mass is impregnated with each of the dilutions. Both orders of impregnation are suitable to prepare the desired combination dosage form.
• the starting material for the preparation of the activated potentiated form that comprise the pharmaceutical composition of the invention is polyclonal, animal-raised antibody to the corresponding antigen, namely, CD4 receptor.
• the desired antigen may be injected as immunogen into a laboratory animal, preferably, rabbits.
• Polyclonal antibodies to CD4 receptor may be obtained using the whole molecule of human CD4 receptor of the following sequence: SEQ ID NO: 1
• Lys Lys Ser lie Gin Phe His Trp Lys Asn Ser Asn Gin lie Lys
• polypeptide fragment of CD4 receptor chosen, for example, from the following amino-acid sequences:
• Lys Lys Ser lie Gin Phe His Trp Lys Asn Ser Asn Gin lie Lys
• the exemplary procedure for preparation of the starting polyclonal antibodies to CD4 receptor may be described as follows. In 7-9 days before blood sampling, 1-3 intravenous injections of the desired antigen are made to the rabbits to increase the level of polyclonal antibodies in the rabbit blood stream. Upon immunization, blood samples are taken to test the antibody level. Typically, the maximum level of immune reaction of the soluble antigen is achieved within 40 to 60 days after the first injection of the antigen. Upon completion of the first immunization cycle, rabbits have a 30-day rehabilitation period, after which re-immunization is performed with another 1 -3 intravenous injections.
• the immunized rabbits' blood is collected from rabbits and placed in a 50ml centrifuge tube.
• Product clots formed on the tube sides are removed with a wooden spatula, and a rod is placed into the clot in the tube center.
• the blood is then placed in a refrigerator for one night at the temperature of about 40°C.
• the clot on the spatula is removed, and the remaining liquid is centrifuged for 10 min at 13,000 rotations per minute. Supernatant fluid is the target antiserum.
• the obtained antiserum is typically yellow.
• 10 ml of the antiserum of rabbits is diluted twofold with 0.15 M NaCI, after which 6.26g Na 2 S04 is added, mixed and incubated for 12-16 hours at 4°C.
• the sediment is removed by centrifugation, diluted in 10ml of phosphate buffer and dialyzed against the same buffer during one night at ambient temperature. After the sediment is removed, the solution is applied to a DEAE-cellulose column balanced by phosphate buffer.
• the antibody fraction is determined by measuring the optical density of the eluate at 280 nm.
• the isolated crude antibodies are purified using affine chromatography method by attaching the obtained antibodies to CD4 antigen located on the insoluble matrix of the chromatography media, with subsequent elution by concentrated aqueous salt solutions.
• the resulting buffer solution is used as the initial solution for the homeopathic dilution process used to prepare the activated potentiated form of the antibodies.
• the preferred concentration of the initial matrix solution of the antigen-purified polyclonal rabbit antibodies to CD4 receptor is 0.5 to 5.0 mg/ml, preferably, 2.0 to 3.0 mg/ml.
• the activated-potentiated form of an antibody to CD4 receptor may be prepared from an initial solution by homeopathic potentization, preferably using the method of proportional concentration decrease by serial dilution of 1 part of each preceding solution (beginning with the initial solution) in 9 parts (for decimal dilution), or in 99 parts (for centesimal dilution), or in 999 parts (for millesimal dilution) of a neutral solvent, starting with a concentration of the initial solution of antibody in the solvent, preferably, water or a water-ethyl alcohol mixture, in the range from about 0.5 to about 5.0 mg/ml, coupled with external impact.
• the external impact involves multiple vertical shaking (dynamization) of each dilution.
• a 12-centesimal dilution (denoted C12) one part of the initial matrix solution of antibodies to CD4 receptor with the concentration of 3.0 mg/ml is diluted in 99 parts of neutral aqueous or aqueous-alcohol solvent (preferably, 15%-ethyl alcohol) and then vertically shaked many times (10 and more) to create the 1st centesimal dilution (denoted as C1 ).
• the 2nd centesimal dilution (C2) is prepared from the 1 st centesimal dilution C1. This procedure is repeated 1 1 times to prepare the 12th centesimal dilution C12.
• the 12th centesimal dilution C12 represents a solution obtained by 12 serial dilutions of one part of the initial matrix solution of antibodies to gamma interferon with the concentration of 3.0 mg/ml in 99 parts of a neutral solvent in different containers, which is equivalent to the centesimal homeopathic dilution C12. Similar procedures with the relevant dilution factor are performed to obtain dilutions C30, C50 and C 200. The intermediate dilutions may be tested in a desired biological model to check activity.
• the preferred activated-potentiated form for the composition of the invention are a mixture of C12, C30, and C50 dilutions or C12, C30 and C200 dilutions.
• each component of the composition e.g., C12, C30, C50, C200
• the next-to-last dilution is obtained (e.g., until C11 , C29, and C199 respectively)
• one part of each component is added in one container according to the mixture composition and mixed with the required quantity of the solvent (e.g. with 97 parts for centesimal dilution).
• the active substance is possible to use as mixture of various homeopathic dilutions, e.g. decimal and/or centesimal (D20, C30, C100 or C12, C30, C50 or C12, C30, C200, etc.), the efficiency of which is determined experimentally by testing the dilution in a suitable biological model, for example, in models described in the examples herein.
• various homeopathic dilutions e.g. decimal and/or centesimal (D20, C30, C100 or C12, C30, C50 or C12, C30, C200, etc.
• the vertical shaking may be substituted for external exposure to ultrasound, electromagnetic field or any similar external impact procedure accepted in the homeopathic art.
• the pharmaceutical composition of the invention may be in the form of a liquid or in the solid unit dosage form.
• the preferred liquid carrier is water or water-ethyl alcohol mixture.
• the solid unit dosage form of the pharmaceutical composition of the invention may be prepared by impregnating a solid, pharmaceutically acceptable carrier with the mixture of the activated potentiated form aqueous or aqueous-alcohol solutions of active component.
• the carrier may be impregnated consecutively with each requisite dilution. Both orders of impregnation are acceptable.
• the pharmaceutical composition in the solid unit dosage form is prepared from granules of the pharmaceutically acceptable carrier which was previously saturated with the aqueous or aqueous-alcoholic dilutions of the activated potentiated form of antibodies CD4 receptor.
• the solid dosage form may be in any form known in the pharmaceutical art, including a tablet, a capsule, a lozenge, and others.
• inactive pharmaceutical ingredients one can use glucose, sucrose, maltose, amylum, isomaltose, isomalt and other mono- olygo- and polysaccharides used in manufacturing of pharmaceuticals as well as technological mixtures of the above mentioned inactive pharmaceutical ingredients with other pharmaceutically acceptable excipients, for example isomalt, crospovidone, sodium cyclamate, sodium saccharine, anhydrous citric acid etc), including lubricants, disintegrants, binders and coloring agents.
• the preferred carriers are lactose and isomalt.
• the pharmaceutical dosage form may further include standard pharmaceutical excipients, for example, microcrystalline cellulose, magnesium stearate and citric acid.
• lactose 100-300 pm granules of lactose are impregnated with aqueous or aqueous-alcoholic solutions of the activated-potentiated form of antibodies to CD4 receptor in the ratio of 1 kg of antibody solution to 5 or 10 kg of lactose (1 :5 to 1 :10).
• the lactose granules are exposed to saturation irrigation in the fluidized boiling bed in a boiling bed plant (e.g. "Huttlin Pilotlab" by Huttlin GmbH) with subsequent drying via heated air flow at a temperature below 40°C.
• the estimated quantity of the dried granules (10 to 34 weight parts) saturated with the activated potentiated form of antibodies is placed in the mixer, and mixed with 25 to 45 weight parts of "non-saturated" pure lactose (used for the purposes of cost reduction and simplification and acceleration of the technological process without decreasing the treatment efficiency), together with 0.1 to 1 weight parts of magnesium stearate, and 3 to 10 weight parts of microcrystalline cellulose.
• the obtained tablet mass is uniformly mixed, and tableted by direct dry pressing (e.g., in a Korsch - XL 400 tablet press) to form 150 to 500 mg round pills, preferably, 300 mg.
• the combination of the invention is administered from once daily to four times daily, preferably twice daily, each administration including one or two combination unit dosage forms.
• Human peripheral blood mononuclear cells were isolated from blood of a seronegative healthy donor by centrifugation on a Ficoll-Hypaque density gradient. The cells were stimulated for 3 days with 1 pg/mL of phytohemagglutinin P and 5 lU/mL of recombinant human interleukin-2.
• the supernatant fluids were collected on day 7 after infection of cells.
• the products' activity was measured by the inhibition of level of core nucleocapsid p24 protein in the supernatant fluid from human peripheral blood mononuclear cells using Retrotek Elisa kit.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Medicinal Chemistry (AREA)
• Immunology (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Molecular Biology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Virology (AREA)
• Biochemistry (AREA)
• Biophysics (AREA)
• Genetics & Genomics (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Mycology (AREA)
• Microbiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Alternative & Traditional Medicine (AREA)
• Hematology (AREA)
• Endocrinology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Peptides Or Proteins (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (2)

Publications (2)

Family

ID=44899160

Family Applications (1)

Country Status (16)

Cited By (1)

Families Citing this family (7)

Citations (5)

Family Cites Families (11)

• 2010
  • 2010-08-06 RU RU2010133046/15A patent/RU2517084C2/ru not_active IP Right Cessation
• 2011
  • 2011-07-15 EA EA201300138A patent/EA029791B1/ru not_active IP Right Cessation
  • 2011-07-15 UA UAA201300111A patent/UA112752C2/uk unknown
  • 2011-07-15 SG SG2013009022A patent/SG187735A1/en unknown
  • 2011-07-15 ES ES201390020A patent/ES2415029R1/es active Pending
  • 2011-07-15 CN CN2011800388401A patent/CN103179987A/zh active Pending
  • 2011-07-15 US US13/135,897 patent/US20120263726A1/en not_active Abandoned
  • 2011-07-15 WO PCT/IB2011/002355 patent/WO2012017322A2/en not_active Ceased
  • 2011-07-15 PH PH1/2013/500233A patent/PH12013500233A1/en unknown
  • 2011-07-15 IT IT000636A patent/ITTO20110636A1/it unknown
  • 2011-07-15 JP JP2013522317A patent/JP2013535483A/ja active Pending
  • 2011-07-15 GB GB1303865.8A patent/GB2496356A/en not_active Withdrawn
  • 2011-07-15 CA CA2807523A patent/CA2807523A1/en not_active Abandoned
  • 2011-07-15 AU AU2011287286A patent/AU2011287286A1/en not_active Abandoned
  • 2011-07-15 DE DE112011102639T patent/DE112011102639T5/de not_active Withdrawn
  • 2011-07-15 MX MX2013001450A patent/MX2013001450A/es unknown
• 2013
  • 2013-05-15 US US13/894,476 patent/US20130315964A1/en not_active Abandoned

Patent Citations (5)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events